The Goldman Sachs Group Has Lowered Expectations for HealthEquity (NASDAQ:HQY) Stock Price

HealthEquity (NASDAQ:HQY) had its price target decreased by research analysts at The Goldman Sachs Group from $107.00 to $94.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 8.10% from the stock’s previous close.

HQY has been the topic of several other research reports. Raymond James upgraded shares of HealthEquity from an “outperform” rating to a “strong-buy” rating and dropped their target price for the company from $120.00 to $115.00 in a report on Tuesday. Wells Fargo & Company upped their target price on HealthEquity from $110.00 to $125.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Barrington Research reiterated an “outperform” rating and issued a $112.00 target price on shares of HealthEquity in a report on Friday, March 14th. KeyCorp dropped their price target on HealthEquity from $120.00 to $110.00 and set an “overweight” rating on the stock in a research note on Monday, March 24th. Finally, Royal Bank of Canada raised their price objective on shares of HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, HealthEquity currently has a consensus rating of “Buy” and a consensus target price of $112.23.

HealthEquity Stock Down 2.1 %

Shares of NASDAQ HQY opened at $86.96 on Thursday. The company’s 50 day moving average price is $103.63 and its 200-day moving average price is $95.91. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20. HealthEquity has a 52-week low of $65.01 and a 52-week high of $115.59. The company has a market capitalization of $7.52 billion, a P/E ratio of 79.78, a price-to-earnings-growth ratio of 1.60 and a beta of 0.62.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the completion of the sale, the director now directly owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Holocene Advisors LP bought a new position in HealthEquity during the 3rd quarter valued at $1,246,000. HighTower Advisors LLC raised its holdings in shares of HealthEquity by 4.8% in the fourth quarter. HighTower Advisors LLC now owns 95,075 shares of the company’s stock valued at $9,122,000 after purchasing an additional 4,370 shares during the last quarter. Geneva Capital Management LLC lifted its position in shares of HealthEquity by 24.6% during the fourth quarter. Geneva Capital Management LLC now owns 1,048,903 shares of the company’s stock valued at $100,642,000 after purchasing an additional 206,894 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of HealthEquity by 165.7% during the third quarter. BNP Paribas Financial Markets now owns 20,437 shares of the company’s stock valued at $1,673,000 after purchasing an additional 12,745 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in HealthEquity by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,086,811 shares of the company’s stock worth $104,280,000 after purchasing an additional 25,004 shares during the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.